UK Medical Cannabis Education
Medical Weed UK: Laws, NHS Guidance, Prescriptions and Patient Safety
A detailed educational guide to medical cannabis in the United Kingdom, explaining the legal framework, scientific evidence, licensed medicines, clinical supervision and important health considerations.
Updated: October 2026
What Is Medical Weed?
The expression "medical weed" is an informal term commonly used to describe cannabis-based products used for medical purposes.
In healthcare and regulatory settings, the more precise terminology is "medical cannabis" or "cannabis-based products for medicinal use".
These terms refer to a range of preparations containing cannabinoids, which are compounds associated with the cannabis plant.
Medical cannabis is not a single medicine. Different preparations can contain different active ingredients and have different clinical applications, risks and regulatory classifications.
This distinction is essential because scientific evidence supporting one specific cannabinoid medicine cannot automatically be applied to every cannabis-containing product.
Is Medical Weed Legal in the UK?
In November 2018, UK regulations were amended to allow certain cannabis-based products for medicinal use to be prescribed under defined conditions.
The change followed increasing attention to the potential clinical role of specific cannabinoid-based medicines.
However, the amendment did not legalise recreational cannabis.
Cannabis remains a Class B controlled drug under the Misuse of Drugs Act 1971. Unauthorised possession and supply remain subject to criminal law.
Medical cannabis regulations provide a specific legal framework for qualifying medicines and prescriptions.
The legal status of a product depends on its composition, classification and relevant authorisations.
Readers should distinguish between regulated medical products and ordinary commercial cannabis preparations.
Medical Cannabis vs Recreational Cannabis
Medical cannabis and recreational cannabis are often discussed together, but their legal and clinical contexts differ.
| Characteristic | Medical Cannabis | Recreational Cannabis |
|---|---|---|
| Primary context | Clinical treatment under applicable regulations | Non-medical use |
| UK legal status | Permitted under defined medical conditions | Unauthorised possession and supply remain unlawful |
| Clinical supervision | Required where applicable to prescribed treatment | Not part of a regulated treatment plan |
| Quality oversight | Subject to applicable medicines requirements | Unregulated products may have uncertain composition |
| Medical evidence | Varies by medicine and indication | Not established by recreational marketing claims |
Understanding THC and CBD
Two of the best-known cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD).
THC can cause intoxication and impair concentration, coordination and judgement.
CBD does not typically produce the same intoxicating effects, although it can still cause side effects and interact with other medicines.
THC in Medical Research
THC has been investigated for particular medical applications, including its role in certain prescription medicines.
However, its psychoactive effects create important safety considerations.
CBD in Medical Research
Specific pharmaceutical cannabidiol preparations have demonstrated benefits for certain severe epilepsy syndromes.
This does not mean that ordinary CBD products are equivalent to licensed cannabidiol medicines.
For a detailed comparison, read THC vs CBD: Understanding the Differences.
What Medical Cannabis Treatments Are Recognised in the UK?
The UK medical framework includes several specific cannabinoid-based medicines.
Epidyolex
Epidyolex is a cannabidiol-based prescription medicine authorised for particular severe epilepsy syndromes.
Its clinical use depends on the relevant indication and specialist supervision.
Sativex
Sativex is a prescription oromucosal spray containing THC and CBD.
NICE recommends it under defined conditions for moderate to severe spasticity associated with multiple sclerosis when other pharmacological treatments have not been effective.
Nabilone
Nabilone is a synthetic cannabinoid medicine.
NICE recommends considering it as an additional treatment for adults experiencing persistent chemotherapy-related nausea and vomiting despite optimised conventional treatment.
Why Specific Medicines Matter
Clinical recommendations apply to particular medicines, patient groups and medical conditions.
Evidence supporting one medicine does not demonstrate that all cannabis products have the same benefits or safety profile.
Medical Cannabis and the NHS
Medical cannabis prescribing on the NHS remains limited.
The NHS explains that only a relatively small number of patients are likely to receive cannabis-based medicines through NHS services.
Relevant clinical circumstances include certain severe epilepsy syndromes, chemotherapy-related nausea and vomiting, and selected cases of multiple sclerosis-related spasticity.
These are not broad approvals for every cannabis preparation.
The relevant medicine, clinical evidence, individual circumstances and specialist assessment all matter.
See the official NHS medical cannabis information.
Why Specialist Medical Oversight Matters
Cannabis-based medicines can affect the nervous system and may interact with other treatments.
Clinical oversight helps ensure that decisions consider both potential benefits and possible harms.
For most unlicensed cannabis-based products for medicinal use, the initial prescribing decision must involve an appropriately qualified specialist medical practitioner.
Different prescribing rules apply to certain licensed medicines.
NICE also describes circumstances where shared-care arrangements may be appropriate.
Medical Cannabis and Chronic Pain
Chronic pain is one of the most frequently discussed topics in medical cannabis research.
However, the evidence remains insufficient to support broad claims about effectiveness.
NICE guideline NG144 recommends against offering THC, nabilone, dronabinol or THC:CBD combinations for chronic pain in adults.
NICE also recommends against offering CBD for chronic pain outside a clinical trial.
These recommendations demonstrate why medical cannabis information must distinguish between emerging research and established clinical care.
Medical Cannabis and Epilepsy
Certain severe epilepsy syndromes are among the areas where cannabinoid-based medicines have demonstrated clinical benefits.
Specific cannabidiol medicines are used under defined conditions for certain treatment-resistant epilepsy syndromes.
Their use involves specialist assessment and ongoing monitoring.
The clinical evidence does not establish that ordinary cannabis oils or commercial CBD products can replace prescribed epilepsy treatments.
Medical Cannabis and Multiple Sclerosis
Multiple sclerosis is a condition affecting the central nervous system.
Some individuals experience spasticity, involving muscle stiffness and involuntary spasms.
NICE recommends a defined trial of THC:CBD spray for selected adults with moderate to severe spasticity when other medicines have not been effective.
Treatment must be initiated and supervised by an appropriately experienced specialist.
Potential Side Effects of Medical Cannabis
Like other medicines, cannabis-based treatments may cause adverse effects.
Dizziness and Drowsiness
Some cannabinoid medicines can cause tiredness, dizziness or reduced alertness.
Changes in Mood and Perception
THC-containing medicines can affect mood, perception and concentration.
Interactions With Other Medicines
Cannabinoids can interact with other prescribed treatments, making medical review important.
Liver-Related Concerns
Certain cannabidiol medicines can affect liver function. Clinical monitoring may therefore be required.
Dependence and Misuse
THC-containing products can present dependence and misuse concerns.
These risks form part of clinical assessment and prescribing decisions.
Medical Safety Comes First
A cannabis-based medicine should be evaluated according to its clinical evidence, legal status, potential side effects and individual patient needs.
Advertising claims cannot replace professional medical assessment or medicines regulation.
Medical Cannabis and Young People
Special caution is necessary when considering cannabinoid medicines for children and adolescents.
The developing brain is particularly vulnerable to the effects of psychoactive substances.
NICE advises additional consideration of psychological, emotional, cognitive and neurological development when prescribing cannabinoid medicines to young people.
Treatment decisions should involve appropriate specialist healthcare professionals.
Medical Cannabis and Pregnancy
Cannabis exposure during pregnancy and breastfeeding raises important concerns.
Cannabinoids may affect biological processes relevant to development, and evidence about the safety of many preparations remains limited.
NICE advises clinicians to consider pregnancy and breastfeeding when evaluating cannabis-based medicines.
Medical Cannabis vs Cannabis Oil
The term "cannabis oil" can refer to products with substantially different compositions.
Some preparations contain cannabidiol, while others contain THC or combinations of cannabinoids.
A commercial cannabis oil should not automatically be treated as a regulated medical product.
Read our related educational guide: Cannabis Oil UK: Legal and Health Considerations.
Common Myths About Medical Weed in the UK
Myth: Medical Cannabis Is Legal for Everyone
UK law permits specific medical uses under defined conditions. Recreational cannabis remains controlled.
Myth: Every Cannabis Product Is a Medicine
A cannabis-containing product is not automatically an authorised medicine.
Myth: Natural Medicines Have No Risks
Plant-derived compounds can cause side effects and interact with other medicines.
Myth: Medical Cannabis Is Proven for Every Condition
Clinical evidence differs significantly between medicines and conditions.
Myth: Online Availability Establishes Legality
The presence of a product on a website does not establish that it can lawfully be possessed, supplied or imported.
Frequently Asked Questions
Is medical weed legal in the UK?
Certain cannabis-based medicines are legal under defined prescribing and regulatory conditions. Recreational cannabis remains controlled.
Is medical cannabis available on the NHS?
Certain cannabinoid medicines may be prescribed through NHS services for specific clinical indications. Availability remains limited.
Is medical cannabis the same as CBD?
No. Medical cannabis is a broad category that may include different cannabinoids, including THC and CBD.
Can medical cannabis treat chronic pain?
NICE does not recommend the listed cannabis-based medicines for routine management of chronic pain in adults.
Can medical cannabis cause side effects?
Yes. Potential adverse effects include dizziness, sedation, psychological effects and interactions with medicines.
Are all medical cannabis products licensed?
No. UK regulations distinguish between licensed medicines and certain unlicensed preparations prescribed under specific conditions.
Does a medical cannabis prescription make recreational cannabis legal?
No. A prescription applies to the specific medicine and patient under the relevant legal framework.
Is medical cannabis safe for children?
Some specific cannabinoid medicines may be used for particular paediatric conditions under specialist supervision. This does not mean that cannabis products are generally safe for children.
Conclusion
Medical weed in the UK is best understood through the framework of regulated cannabis-based medicines.
Although certain cannabinoid medicines have recognised clinical applications, evidence varies significantly between conditions.
The legal medical framework does not extend to unrestricted recreational cannabis use.
Readers should distinguish between authorised medicines, specialist-prescribed products and ordinary commercial cannabis preparations.
Reliable information from the NHS, NICE and UK medicines regulators remains essential for understanding the benefits, limitations and risks of medical cannabis.